

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4862683

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HOWARD COTTAM	10/10/2017
EMMANUEL OJO-AMAIZE	10/16/2017
EMEKA NCHEKWUBE	10/09/2017
OLUSOLA OYEMADE	10/17/2017
RECEIVING PARTY DATA	
Name:	IMMUNE MODULATION, INC.
Street Address:	P.O. BOX 998
City:	BLOOMINGTON
State/Country:	CALIFORNIA
Postal Code:	92316-0998
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15556730
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	858-350-2300
Email:	lford@wsgr.com, patentdocket@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1050
ATTORNEY DOCKET NUMBER:	52925-701.831
NAME OF SUBMITTER:	LORI FORD
SIGNATURE:	/Lori Ford/
DATE SIGNED:	03/12/2018
Total Attachments: 4	
source=52925-701-831_Executed_Assignment#page1.tif	
source=52925-701-831_Executed_Assignment#page2.tif	
source=52925-701-831_Executed_Assignment#page3.tif	

PATENT ASSIGNMENT

Docket Number 52925-701 831

WHEREAS, the undersigned:

- | | | | |
|---|---|--|---|
| 1. Howard COTTAM
3280 Oak Wood Lane
Escondido, CA 92027 | 2. Emmanuel OJO-AMAIZE
11250 Cypress Avenue
Fontana, CA 92337 | 3. Emeka NCHEKWUBE
5390 Little Usan Road
Morgan Hill, CA 95037 | 4. Oluola OYEMADE
7777 Milliken Avenue, Suite 360
Rancho Cucamonga, CA 91730-6782 |
|---|---|--|---|

(hereinafter "inventor(s)"), have invented certain new and useful improvements in

HYPOESTOXIDE, DERIVATIVES, RELATED COMPOUNDS, AND AGONISTS THEREOF FOR TREATMENT OR PREVENTION OF NEURODEGENERATIVE DISEASES

for which application serial number 15/556,710 was filed on September 8, 2017 in the United States Patent and Trademark Office; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, Immune Modulation, Inc., a corporation of the State of California, having a place of business at 777 Milliken Avenue, Suite 360, Rancho Cucamonga, CA, 91730-6782, USA, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said inventor(s) (hereinafter collectively referred to as "inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said inventor(s) to have been received in full from said Assignee:

1. Said inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or resulting from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said inventions; and (f) for legal proceedings involving said inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and *inter partes* actions; provided, however, that reasonable expenses incurred by said inventor(s) in providing such cooperation shall be paid for by said Assignee.


3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said inventor(s), their respective heirs, legal representatives and assigns.

4. Said inventor(s) hereby warrant, represent and covenant that said inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: <u>10/10/17</u>		Date: _____	_____
	Howard COTTAM		Emeka NCHEKWUBE
Date: _____	_____	Date: _____	_____
	Emmanuel OJO-AMAIZE		Oluola OYEMADE

RECEIVED AND AGREED TO BY ASSIGNEE:

Immune Modulation, Inc.

Date: _____

Signature: _____

Name/Title: Emmanuel A. Ojo-Amaize, Ph.D., Founder, President & CEO

PATENT ASSIGNMENT

Docket Number 52925-701.631

WHEREAS, the undersigned:

- 1. Howard COTTAM
3280 Oak Wood Lane
Escondido, CA 92027
- 2. Emmanuel OJO-AMAIZE
11250 Cypress Avenue
Fountain, CA 92337
- 3. Emeka NCHEKWUBE
5390 Little Uvas Road
Morgan Hill, CA 95037
- 4. Olusola OYEMADE
7777 Milliken Avenue, Suite 360
Rancho Cucamonga, CA 91730-6782

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

HYPOESTOXIDE, DERIVATIVES, RELATED COMPOUNDS, AND AGONISTS THEREOF FOR TREATMENT OR PREVENTION OF NEURODEGENERATIVE DISEASES

for which application serial number 15/556,730 was filed on September 8, 2017 in the United States Patent and Trademark Office; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, Immune Modulation, Inc., a corporation of the State of California, having a place of business at 777 Milliken Avenue, Suite 360, Rancho Cucamonga, CA 91730-6782, USA, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Howard COTTAM

Date: _____
Emeka NCHEKWUBE

Date: 10/16/2017
Emmanuel OJO-AMAIZE

Date: _____
Olusola OYEMADE

RECEIVED AND AGREED TO BY ASSIGNEE:

Immune Modulation, Inc.

Date: 10/16/2017

Signature: Emmanuel A. Ojo-Amaize

Name/Title: Emmanuel A. Ojo-Amaize, Ph.D., Founder, President & CEO

PATENT ASSIGNMENT

Docket Number 52925-701.031

WHEREAS, the undersigned:

- 1. Howard COTTAM
1280 Oak Wood Lane
Escondido, CA 92027
- 2. Emmanuel OJO-AMAIZE
11250 Cypress Avenue
Fontana, CA 92337
- 3. Emeke NCHEKWUBE
5396 Little Usas Road
Morgan Hill, CA 95037
- 4. Olusola OYEMADE
7777 Milliken Avenue, Suite 360
Rancho Cucamonga, CA 91730-6782

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

HYPOESTOXIDE, DERIVATIVES, RELATED COMPOUNDS, AND AGONISTS THEREOF FOR TREATMENT OR PREVENTION OF NEURODEGENERATIVE DISEASES

for which application serial number 13,226,730, was filed on September 8, 2017, in the United States Patent and Trademark Office; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, Immune Modulation, Inc., a corporation of the State of California, having a place of business at 777 Milliken Avenue, Suite 360, Rancho Cucamonga, CA 91730-6782, USA, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventor(s)"), and in and to any and all patents, Inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or issuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including a full right to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the date written below:

Date: _____
Howard COTTAM

Date: 10/9/17 _____
Emeka NCHEKWUBE

Date: _____
Emmanuel OJO-AMAIZE

Date: _____
Olusola OYEMADE

RECEIVED AND AGREED TO BY ASSIGNEE:

Immune Modulation, Inc.

Date: _____

Signature: _____

Name/Title: Emmanuel A. Ojo-Amaize, Ph.D., Founder, President & CEO

PATENT ASSIGNMENT

Docket Number 52925-701.851

WHEREAS, the undersigned,

- | | | | |
|---|---|--|--|
| 1. Howard COTTAM
3280 Oak Wood Lane
Escondido, CA 92027 | 2. Emmanuel OJO-AMAIZE
11250 Cypress Avenue
Fontana, CA 92337 | 3. Emeka NCHEKWURE
5390 Little Uvas Road
Morgan Hill, CA 95037 | 4. Olusola OYEMADE
7777 Milliken Avenue, Suite 369
Rancho Cucamonga, CA 91750-6782 |
|---|---|--|--|

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

HYPOSTOXIDE, DERIVATIVES, RELATED COMPOUNDS, AND AGONISTS THEREOF FOR TREATMENT OR PREVENTION OF NEURODEGENERATIVE DISEASES

for which application serial number 15/556,730, was filed on September 8, 2017 in the United States Patent and Trademark Office; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, Immune Modulation, Inc., a corporation of the State of California, having a place of business in 777 Milliken Avenue, Suite 369, Rancho Cucamonga, CA, 91750-6782, USA (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below.

Date: _____
Howard COTTAM

Date: _____
Emeka NCHEKWURE

Date: _____
Emmanuel OJO-AMAIZE

Date: 10/17/17
Olusola OYEMADE

RECEIVED AND AGREED TO BY ASSIGNEE:

Immune Modulation, Inc.

Date: _____

Signature: _____
Name/Title: Emmanuel A. Ojo-Amaize, Ph.D., Founder, President & CEO